Skip to content
Wenlo
Sign in
← Markets

Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated (VRTX) — Form 8-K: Current report

8-KVRTXFiled Oct 20, 2026, 4:09 PM ET· Period Oct 20, 2026

AI-generated summary

Vertex Pharmaceuticals Incorporated announced the appointment of Daniel Brennan to its board of directors and Audit and Finance Committee on October 20, 2026. In connection with his appointment, the size of the board was increased. Mr. Brennan received a $400,000 restricted stock unit award that will vest in October 2027.

View original filing on SEC.gov (opens SEC EDGAR)

Key facts

  • Item 5.02 · Executive or director change or pay arrangement

More VRTX filings

Not investment advice. Summaries can contain errors; the SEC filing is the official record.